Comparison of results of a pilot study of alternating vincristine/ doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 50, Issue 1, 2008, Pages 33-36

  Arndt, Carola A S ^a,g   Hawkins, Douglas S ^b   Meyer, William H ^c   Sencer, Susan F ^d   Neglia, Joseph P ^e   Anderson, James R ^f  

^a MAYO CLINIC   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^g MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Intermediate risk rhabdomyosarcoma; IRS IV; Rhabdomyosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TREATMENT FAILURE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HUMANS; IFOSFAMIDE; INFANT; PILOT PROJECTS; RHABDOMYOSARCOMA; SURVIVAL RATE; VINCRISTINE;

EID: 36849009613     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21093     Document Type: Article

References (23)

1. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004;30:269-280.
2. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study v. J Pediatr Hematol Oncol 2001;23:215-220.
3. Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study-i. A final report. Cancer 1988;61:209-220.
4. Maurer HM, Gehan EA, Beltangady M, et al. The intergroup rhabdomyosarcoma study-ii. Cancer 1993;71:1904-1922.
5. Crist W, Gehan EA, Ragab AH, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol 1995;13:610-630.
6. Womer RB. The intergroup rhabdomyosarcoma studies come of age. Cancer 1993;71:1719-1721.
7. Tan C, Etcubanas E, Wollner N, et al. Adriamycin - An antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973;32:9-17.
8. O'Bryan RM, Luce JK, Talley RW, et al. Phase ii evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
9. Bisogno G, Ferrari A, Bergeron C, et al. The ivado regimen - A pilot study with ifosfamide, vincristine, actinomycin d, and doxorubicin in children with metastatic soft tissue sarcoma: A pilot study of behalf of the european pediatric soft tissue sarcoma study group. Cancer 2005;103:1719-1724.
10. Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68.
11. Simbre VC, Duffy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy: Implications for children. Paediatr Drugs 2005;7:187-202.
12. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-iv: Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-3102.
13. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994;16:286-295.
14. Arndt C, Tefft M, Gehan E, et al. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study (irs) iv pilot study. J Pediatr Hematol Oncol 1997;19:124-129.
15. Arndt C, Morgenstern B, Wilson D, et al. Renal function in children and adolescents following 72 g/m2 of ifosfamide. Cancer Chemother Pharmacol 1994;34:431-433.
16. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003;41:190-197.
17. Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. [see comment]. N Engl J Med 1989;321:136-142.
18. Arndt CA, Nascimento AG, Schroeder G, et al. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide. Eur J Cancer 1998;34:1224-1229.
19. Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the intergroup rhabdomyosarcoma study group protocols irs-ii through -iv, 1978-1997. Med Pediatr Oncol 2002;38:22-32.
20. Norton L, Simon R. The norton-simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
21. Womer RB, Daller RT, Fenton JG, et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87-94.
22. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase i inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
23. Pappo AS, Lyden E, Breitfeld PP, et al. Irinotecan (cpt-11) is active against pediatric rhabdomyosarcoma (rms): A phase ii window trial from the soft tissue sarcoma committee (sts) of the children's oncology group (cog). Proc Am Soc Clin Oncol 2002;21:393a.